Gilead Sciences (GILD) Income from Continuing Operations (2009 - 2026)

Gilead Sciences has reported Income from Continuing Operations for 18 years, with the latest figure at 2021000000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 53.69% year-over-year to 2021000000.0; the trailing twelve-month figure through Mar 2026 stood at 9562000000.0 (up 60.3% YoY), and the FY2025 full-year result was 8510000000.0, up 1676.62% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 2021000000.0, down from 2528000000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 3052000000.0 in Q3 2025, with the low at 4171000000.0 in Q1 2024.
• Historically, Income from Continuing Operations has averaged 1266647058.82 across 5 years, with a median of 1615000000.0 in 2024.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 8100.0% — and 2024, when it slumped 523.88%.
• Gilead Sciences' Income from Continuing Operations stood at 1633000000.0 in 2022, then dropped by 13.29% to 1416000000.0 in 2023, then advanced by 25.85% to 1782000000.0 in 2024, then soared by 41.86% to 2528000000.0 in 2025, then dropped by 20.06% to 2021000000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 2021000000.0 (Q1 2026), 2528000000.0 (Q4 2025), and 3052000000.0 (Q3 2025), per Business Quant data.